These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition. Yang Z; Wu D; Chen Y; Min Z; Quan Y Cancer Biol Ther; 2019; 20(9):1195-1205. PubMed ID: 31063022 [TBL] [Abstract][Full Text] [Related]
4. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Yoneura N; Takano S; Yoshitomi H; Nakata Y; Shimazaki R; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Miyazaki M; Ohtsuka M Int J Mol Med; 2018 Aug; 42(2):821-830. PubMed ID: 29749431 [TBL] [Abstract][Full Text] [Related]
5. Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor. Nam S; Khawar IA; Park JK; Chang S; Kuh HJ Biochem Biophys Res Commun; 2019 Jul; 515(1):183-189. PubMed ID: 31133378 [TBL] [Abstract][Full Text] [Related]
6. The p63 Gene Is Regulated by Grainyhead-like 2 (GRHL2) through Reciprocal Feedback and Determines the Epithelial Phenotype in Human Keratinocytes. Mehrazarin S; Chen W; Oh JE; Liu ZX; Kang KL; Yi JK; Kim RH; Shin KH; Park NH; Kang MK J Biol Chem; 2015 Aug; 290(32):19999-20008. PubMed ID: 26085095 [TBL] [Abstract][Full Text] [Related]
7. Glial cell-derived soluble factors increase the metastatic potential of pancreatic adenocarcinoma cells and induce epithelial-to-mesenchymal transition. García-Reyes B; Kuzmanov I; Schneider R; Schneiker B; Efferz P; Kalff JC; Wehner S J Cancer Res Clin Oncol; 2023 Nov; 149(15):14315-14327. PubMed ID: 37572121 [TBL] [Abstract][Full Text] [Related]
8. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379 [TBL] [Abstract][Full Text] [Related]
9. ZNF263 cooperates with ZNF31 to promote the drug resistance and EMT of pancreatic cancer through transactivating RNF126. Zhang J; Chen C; Geng Q; Li H; Wu M; Chan B; Wang S; Sheng W J Cell Physiol; 2024 Jun; 239(6):e31259. PubMed ID: 38515383 [TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028 [TBL] [Abstract][Full Text] [Related]
11. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma. Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2. Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517 [TBL] [Abstract][Full Text] [Related]
13. Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin. Xu J; Zhu W; Xu W; Yao W; Zhang B; Xu Y; Ji S; Liu C; Long J; Ni Q; Yu X Curr Mol Med; 2013 Mar; 13(3):387-400. PubMed ID: 23331011 [TBL] [Abstract][Full Text] [Related]
14. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
15. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Carstens JL; Yang S; Correa de Sampaio P; Zheng X; Barua S; McAndrews KM; Rao A; Burks JK; Rhim AD; Kalluri R Cell Rep; 2021 Apr; 35(2):108990. PubMed ID: 33852841 [TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831 [TBL] [Abstract][Full Text] [Related]
17. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cieply B; Farris J; Denvir J; Ford HL; Frisch SM Cancer Res; 2013 Oct; 73(20):6299-309. PubMed ID: 23943797 [TBL] [Abstract][Full Text] [Related]
19. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
20. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]